Literature DB >> 19151117

Evidence of concurrent immunopathological mechanisms determining the pathology of severe lupus nephritis.

M M Schwartz1, S M Korbet, R S Katz, E J Lewis.   

Abstract

The purpose of this study is to determine whether two distinct histopathological-immunopathological lesions, which have been reported in severe lupus nephritis, diffuse global glomerulonephritis (GN) (WHO IV) and a segmental and necrotising GN (WHO III) can be reported to coexist in a single patient. We examine the evidence of coexistence of these disparate lesions and the prognostic significance in a group of patients with severe lupus nephritis who have been subjected to a common therapeutic regimen by protocol. The simple, reproducible parameter indicating the presence of glomerular capillary necrosis was the presence of crescents. We, therefore, reviewed 39 renal biopsies with diffuse global lupus GN (WHO IV) (Churg, J, Sobin, LH. Lupus nephritis. Renal disease, classification and atlas of glomerular diseases. New York: Igaku-Shoin; 1982. p. 127-149). and used crescents as a surrogate for glomerular necrosis. Peripheral capillary immune deposits were less prominent in WHO IV with crescents compared with those without and resembled the reduced immune deposits seen in severe segmental GN (WHO III >or= 50%). Patients with WHO IV with crescents had decreased survival without end-stage renal disease (P = 0.02), fewer remissions (P = 0.04) and more adverse outcomes (12/22 vs 3/17) (P = 0.02) than those without crescents, and this was similar to patients with WHO III >or=50%. We conclude that, on the basis of immunological and morphological features, WHO IV with crescents appears to be the result of two distinct pathogenetic mechanisms. We propose that diffuse global lupus GN, associated with crescents, is best described as WHO class IV + WHO class III.

Entities:  

Mesh:

Year:  2009        PMID: 19151117     DOI: 10.1177/0961203308095947

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  7 in total

Review 1.  Histopathology of lupus nephritis.

Authors:  Konstantinos Giannakakis; Tullio Faraggiana
Journal:  Clin Rev Allergy Immunol       Date:  2011-06       Impact factor: 8.667

Review 2.  Redefining lupus nephritis: clinical implications of pathophysiologic subtypes.

Authors:  Feng Yu; Mark Haas; Richard Glassock; Ming-Hui Zhao
Journal:  Nat Rev Nephrol       Date:  2017-07-03       Impact factor: 28.314

3.  Long-term renal outcomes of childhood-onset global and segmental diffuse proliferative lupus nephritis.

Authors:  Pornpimol Rianthavorn; Athitaya Buddhasri
Journal:  Pediatr Nephrol       Date:  2015-06-09       Impact factor: 3.714

4.  Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages.

Authors:  Antigoni Triantafyllopoulou; Claus-Werner Franzke; Surya V Seshan; Giorgio Perino; George D Kalliolias; Meera Ramanujam; Nico van Rooijen; Anne Davidson; Lionel B Ivashkiv
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-26       Impact factor: 11.205

5.  Pathological spectrums and renal prognosis of severe lupus patients with rapidly progressive glomerulonephritis.

Authors:  Shasha Chen; Hao Chen; Zhengzhao Liu; Haitao Zhang; Weixin Hu; Zheng Tang; Zhihong Liu
Journal:  Rheumatol Int       Date:  2014-10-04       Impact factor: 2.631

6.  Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy.

Authors:  Tabitha Turner-Stokes; Hannah R Wilson; Massimiliano Morreale; Ana Nunes; Tom Cairns; H Terence Cook; Charles D Pusey; Ruth M Tarzi; Liz Lightstone
Journal:  Kidney Int       Date:  2017-07-24       Impact factor: 10.612

7.  The severity of glomerular endothelial cell injury is associated with infiltrating macrophage heterogeneity in endocapillary proliferative glomerulonephritis.

Authors:  Momoko Arai; Akiko Mii; Tetsuya Kashiwagi; Akira Shimizu; Yukinao Sakai
Journal:  Sci Rep       Date:  2021-06-25       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.